Anticorps se liant au domaine extracellulaire du récepteur tyrosine kinase ALK

Antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK

Antikörper mit Bindung an die extrazelluläre Domäne der Rezeptor-Tyrosinkinase-ALK


The present invention concerns an antibody specific for human ALK (Anaplastic Lymphoma Kinase), in particular a scFv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said antibody is suitable for the local treatment of tumors, in particular glioblastoma.




Download Full PDF Version (Non-Commercial Use)

Patent Citations (15)

    Publication numberPublication dateAssigneeTitle
    EP-1479694-A2November 24, 2004Esbatech AGAnticorps simple chaine ScFv avec des structures définies (régions d'encadrement) stable dans un environnement réducteur
    US-2001021505-A1September 13, 2001Morris Stephan W., A. T. LookALK protein tyrosine kinase/receptor and ligands thereof
    US-2002034768-A1March 21, 2002Anton WellsteinPleiotrophin growth factor receptor for the treatment of proliferative, vascular and neurological disorders
    US-2004132028-A1July 08, 2004Stumpp Michael Tobias, Patrick Forrer, Binz Hans Kaspar, Andreas PluckthunCollection of repeat proteins comprising repeat modules
    US-2004234519-A1November 25, 2004Tso J. Yun, Anton Wellstein, Debra ChaoAnti-pleiotrophin antibodies and methods of use thereof
    US-5529925-AJune 25, 1996St. Jude Children's Research HospitalNucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
    US-5770421-AJune 23, 1998St. Jude Children's Research HospitalHuman ALK protein tyrosine kinase
    US-6174674-B1January 16, 2001St. Jude Children's Research HospitalMethod of detecting a chromosomal rearrangement involving a breakpoint in the ALK or NPM gene
    US-6300064-B1October 09, 2001Morphosys AgProtein/(poly)peptide libraries
    US-6696548-B2February 24, 2004St. Jude Children's Research HospitalAntibodies for recognition of alk protein tyrosine/kinase receptor
    US-6815540-B1November 09, 2004University Of ZurichImmunoglobulin superfamily domains and fragments with increased solubility
    WO-0196394-A2December 20, 2001Georgetown University Medical CenterLa pleiotrophine, recepteur d'un facteur de croissance, utilisable pour le traitement de troubles de nature proliferante, vasculaire et neurologique
    WO-03097697-A2November 27, 2003Esbatech AgImmunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
    WO-2006020684-A2February 23, 2006Institute For Multiple Myeloma And Bone Cancer ResearchProcedes pour reguler la differenciation et traiter le myelome multiple

NO-Patent Citations (56)

    "Antibody Engineering: ,A Practical Approach (Practical Approach Series", 1996, IRL PR, pages: 169
    ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10
    ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402
    AUF DER MAUR A ET AL: "Antigen-independent selection of intracellular stable antibody frameworks", METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 34, no. 2, October 2004 (2004-10-01), pages 215 - 224, XP004526807, ISSN: 1046-2023
    AUF DER MAUR A ET AL: "Direct in vivo screening of intrabody libraries constructed on a highly stable single-chain framework", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 277, no. 47, 22 November 2002 (2002-11-22), pages 45075 - 45085, XP002284890, ISSN: 0021-9258
    AUSUBEL ET AL.,: "Current Protocols in Molecular Biology", 1992, JOHN WILEY & SONS
    BAI RY ET AL.: "Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt an- tiapoptotic signalling pathway", BLOOD, vol. 96, no. 13, 2000, pages 4319 - 4327
    BIRD, SCIENCE, vol. 242, 1988, pages 423 - 426
    BOWDEN ET AL.: "Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 39, 2002, pages 35862 - 35868
    BRUMMELL ET AL., BIOCHEM., vol. 32, 1993, pages 1180 - 1187
    BURKS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 412 - 417
    CHOTHIA, C.; LESK, A. M.: "Canonical structures for the hypervariable regions of immu- noglobulins", J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
    CHOTHIA, C.; NOVOTNY, J.; BRUCCOLERI, R.; KARPLUS, M.: "Domain association in immunoglobulin molecules. The packing of variable domains", J. MOL. BIOL., vol. 186, 1985, pages 651 - 663, XP024011326, DOI: doi:10.1016/0022-2836(85)90137-8
    CHOUDHURI ET AL.: "An Angiogenic Role for the Neurokines Midkine and Pleiotrophin in Tumorigenesis", CANCER RES., vol. 57, 1997, pages 1814 - 1819
    CZUBAYKO ET AL.: "Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth facator pleiotrophin", PNAS, vol. 93, 1996, pages 14753 - 14758
    DE JUAN C. ET AL.: "Genomic organization of a novel glycosylphosphatidylinositol MAM gene expressed in human tissues and tumors", ONCOGENE, vol. 21, 2002, pages 3089 - 3094
    DELSOL G. ET AL.: "A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation", BLOOD, vol. 89, no. 5, 1997, pages 1483 - 1490
    DIRKS WG. ET AL.: "Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines", INTERNATIONAL JOURNAL OF CANCER, vol. 100, 2002, pages 49 - 56, XP002684555, DOI: doi:10.1002/IJC.10435
    DUYSTER J. ET AL.: "Translocations involving anaplastic lymphoma kinase (ALK", ONCOGENE, vol. 20, 2001, pages 5623 - 5637
    E. MEYERS; W. MILLER, CABIOS, vol. 4, 1989, pages 11 - 17
    ERGIN M. ET AL.: "Inhibition'of tyrosine kinase activity induces caspase-dependent apoptosis. in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein", EXPERIMENTAL HEMATOLOGY, vol. 29, 2001, pages 1082 - 1090, XP002626293, DOI: doi:10.1016/S0301-472X(01)00688-9
    FANG ET AL.: "Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer", JBC, vol. 267, 1992, pages 25889
    FIORANI C. ET AL.: "Primary systemic anaplastic large-cell lymphoma (CD30+): advances in biology and current therapeutic approaches", CLINICAL LYMPHOMA, vol. 2, no. 1, 2001, pages 29 - 37
    HARLOW ET AL.: "Antibodies: A'Laboratory Manual", 1999, C.S.H.L. PRESS
    HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883
    IWAHARA T. ET AL.: "Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system", ONCOGENE, vol. 14, 1997, pages 439 - 449, XP009001671, DOI: doi:10.1038/sj.onc.1200849
    KOBAYASHI ET AL., PROTEIN ENG., vol. 12, no. 10, 1999, pages 879 - 884
    KUTOK JL.; ASTER JC.: "Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma", JOURNAL OF CLINICAL ONCOLOGY, vol. 20, no. 17, 2002, pages 3691 - 3702
    LADANYI M.: "Aberrant ALK tyrosine kinase signalling. Different cellular lineages, common oncogenic mechanisms?", AMERICAN JOURNAL OF PATHOLOGY, vol. 157, no. 2, 2000, pages 341 - 345
    LAMANT ET AL.: "Expression of the ALK tyrosine kinase gene in neuroblastoma", AM. J. PATHOL., vol. 156, 2000, pages 1711 - 1721, XP002684556, DOI: doi:10.1016/S0002-9440(10)65042-0
    LI, X.-Q.; HISAOKA, M.; SHI, D.-R.; ZHU, X-Z.; HASHIMOTO, H.: "Expression of Anaplastic Lymphoma Kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases", HUMAN PATHOLOGY, vol. 35, 2004, pages 711 - 721
    LOREN CE. ET AL.: "Identification and characterization of'Dalk: a novel Drosophila melanogaster RTK which drives ERK activation in vivo", GENES TO CELLS, vol. 6, no. 6, 2001, pages 531 - 544
    MAUR, A. ET AL.: "Direct in vivo screening of intrabody libraries constructed on a highly stable single-chain framework", J BIOL CHEM, vol. 277, no. 47, 2002, pages 45075 - 85, XP002289622, DOI: doi:10.1074/jbc.M205264200
    MAUR, A.; ESCHER, D.; BARBERIS, A.: "Antigen-independent selection of stable intracellular single-chain antibodies", FEBS LETT, vol. 508, 2001, pages 407 - 412, XP004324279, DOI: doi:10.1016/S0014-5793(01)03101-5
    MAUR, A.; TISSOT, K.; BARBERIS, A.: "Antigen-independent selection of intracellular stable antibody frameworks", METHODS, vol. 34, 2004, pages 215 - 224, XP004526807, DOI: doi:10.1016/j.ymeth.2004.04.004
    MIYAKE I. ET AL.: "Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines", ONCOGENE, vol. 21, 2002, pages 5823 - 5834
    MORRIS SW. ET AL.: "ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK", ONCOGENE, vol. 14, 1997, pages 2175 - 2188, XP002249141, DOI: doi:10.1038/sj.onc.1201062
    MORRIS SW. ET AL.: "ALK+CD30+ lymphomas: A distinct molecular genetic subtype of non-Hodgkin's lymphoma", BRITISH JOURNAL OF HAEMATOLOGY, vol. 113, 2001, pages 275 - 295
    NEEDLE- MAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453
    O'BRIEN ET AL.: "The angiogenic factor midkine is expressed in bladder cancer and overexpression correlates with a poor outcome in patients with invasive cancer", CANCER RES., vol. 56, 1996, pages 2515 - 2518, XP000857920
    PADLAN, E. A.: "Anatomy of the antibody molecule", MOL IMMUNOL, vol. 31, 1994, pages 169 - 217, XP023681629, DOI: doi:10.1016/0161-5890(94)90001-9
    PAUL, S.: "Antibody Engineering Protocols", vol. 510, 1996, HUMANA PR
    POWERS C. ET AL.: "Pleiotrophin signalling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 16, 2002, pages 14153 - 14158, XP002503924, DOI: doi:10.1074/jbc.m112354200
    PULFORD K. ET AL.: "Anaplastic lymphoma kinase proteins and malignancy", CURRENT OPINION IN HEMATOLOGY, vol. 81, 2001, pages 231 - 236
    PULFORD K. ET AL.: "Anaplastic lymphoma kinase proteins in growth control and cancer", J CELL PHYSIOL, vol. 199, 2004, pages 330 - 358, XP002464691, DOI: doi:10.1002/jcp.10472
    SCHAERER-BRODBECK, C.; A. BARBERIS: "Coupling homologous recombination with growth selection in yeast: a tool for construction of random DNA sequence libraries", BIOTECHNIQUES, vol. 37, no. 2, 2004, pages 202 - 206, XP001246575
    STOICA G E ET AL: "Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 276, no. 20, 18 May 2001 (2001-05-18), pages 16772 - 16779, XP002222815, ISSN: 0021-9258
    STOICA GE ET AL.: "Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 20, 2001, pages 16772 - 16779, XP002222815, DOI: doi:10.1074/jbc.M010660200
    STOICA GE ET AL.: "Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 39, 2002, pages 35990 - 35998, XP002290577, DOI: doi:10.1074/jbc.M205749200
    STOICA GERALD E ET AL: "Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 277, no. 39, 27 September 2002 (2002-09-27), pages 35990 - 35998, XP002290577, ISSN: 0021-9258
    WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
    WEBER D. ET AL.: "Pleiotrophiri can be rate-limiting for pancreatic cancer cell growth", CANCER RESEARCH, vol. 60, 2000, pages 5284 - 5288
    WELLSTEIN ET AL.: "A Heparin-binding Growth Factor Secreted from Breast Cancer Cells Homologous to a Developmentally Regulated Cytokine", JBC, vol. 267, 1992, pages 2582

Cited By (0)

    Publication numberPublication dateAssigneeTitle